Kyverna Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
-1.06 | 228.69 | -100.46% | 0 | 0% |
| P/S |
|
0 | 45.2 | -100% |
|
|
| P/BV |
|
0.5378 | 26.48 | -97.97% |
|
|
| P/FCF |
|
-1.16 | 1017.55 | -100.11% |
|
|
| Ev/Ebitda |
|
-0.3856 | 144.4 | -100.27% |
|
|
| Ev/S |
|
0 | 32.54 | -100% |
|
|
| Ev/FCF |
|
-0.4722 | 732.48 | -100.06% |
|
|
| E/P |
|
-0.9475 | 0.0044 | -21634.09% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | 22.53 | -100% | -283.62 | -100% |
| ROE |
|
-80.74 | 11.58 | -797.21% |
|
|
| ROA |
|
-67.12 | 8.87 | -856.98% |
|
|
| ROIC |
|
0 | 0 | 0% |
|
|
| ROS |
|
0 | 19.77 | -100% |
|
|
| ROCE |
|
-54.29 | 10.53 | -615.57% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.0578 | 0.3943 | -114.66% | -0.175 | -66.97% |
| Nеt Debt/Ebitda |
|
0.6198 | -1.91 | -132.36% |
|
|
| Debt/Ratio |
|
0.0271 | 0.0399 | -32.12% |
|
|
| Debt/Equity |
|
0.1428 | 0.306 | -53.35% |
|
|
| Debt/Net Income |
|
-0.0647 | 0.4495 | -114.38% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0 | 0% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0 | 0% | ||
| DSI |
|
0 | 0 | 0% |
|
|
| Average dividend growth |
|
0 | 0 | 0% |
|
|
| Average percentage for 5 years |
|
0 | 0 | 0% |
|
|
| Average percentage for payments |
|
0 | 0 | 0% |
|
|
| Difference from average difference in sector |
|
0 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
4/10
|
23.25 | 97.39 | -76.13% | ||
| Growth impulse Ebitda in 5 years |
|
386.01 | 102.44 | 276.82% | ||
| Growth impulse Net Income in 5 years |
|
382.87 | 104.12 | 267.72% | ||
| Growth impulse FCF in 5 years |
|
397.67 | -83.33 | -577.22% | ||
| Growth impulse EPS in 5 years |
|
415.16 | 97.05 | 327.78% |
IP Score
4.47/10
